Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lifted by Prossimo Advisors LLC

Prossimo Advisors LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 27.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,488 shares of the pharmaceutical company’s stock after buying an additional 319 shares during the period. Vertex Pharmaceuticals accounts for 1.3% of Prossimo Advisors LLC’s portfolio, making the stock its 26th largest holding. Prossimo Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $605,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in VRTX. Arlington Trust Co LLC boosted its holdings in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares in the last quarter. Fortitude Family Office LLC bought a new position in Vertex Pharmaceuticals during the fourth quarter worth about $30,000. Baystate Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 25 shares during the period. OFI Invest Asset Management bought a new stake in shares of Vertex Pharmaceuticals in the third quarter worth about $25,000. Finally, NBC Securities Inc. bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $34,000. 90.96% of the stock is owned by institutional investors.

Insider Activity

In other news, CAO Kristen Ambrose sold 1,374 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $577,409.76. Following the transaction, the chief accounting officer now owns 9,676 shares in the company, valued at $4,066,242.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Kristen Ambrose sold 1,374 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $577,409.76. Following the completion of the sale, the chief accounting officer now directly owns 9,676 shares of the company’s stock, valued at approximately $4,066,242.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded up $2.99 on Friday, hitting $421.98. The company’s stock had a trading volume of 552,672 shares, compared to its average volume of 1,221,004. Vertex Pharmaceuticals Incorporated has a 1 year low of $320.01 and a 1 year high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The company has a market capitalization of $109.06 billion, a PE ratio of 30.26, a PEG ratio of 1.89 and a beta of 0.39. The company has a 50-day simple moving average of $407.82 and a 200 day simple moving average of $401.00.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, beating the consensus estimate of $3.66 by $1.10. The firm had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the company posted $2.67 EPS. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, May 3rd. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 6th. Truist Financial boosted their target price on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $440.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. Finally, Robert W. Baird downgraded Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 target price for the company. in a research report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $432.18.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.